ER-100 was well tolerated through Day 56 in the first 3 patients with open-angle glaucoma, with no dose-limiting toxicities, serious adverse events, or adverse events of special interest reported Two ...
Get breaking ophthalmic news, device and drug updates, clinical trial coverage, thought-leader perspective, and industry announcements.
B+L Advances Two Ophthalmic Pipeline Therapies in DED and Ocular Surface Pain ...
Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME ...
Topcon Healthcare has launched Oku Digital Health, an AI-powered company focused on using ocular data to support disease detection, referrals, and pharmaceutical research Oku combines AI-supported ...
Harrow completed its acquisition of worldwide rights to Tyrvaya, excluding Japan, for $30 million upfront and up to $70 million in sales-based milestone payments The FDA-approved nasal spray expands ...
Sight Sciences has commercially launched Omni Ultra, its next-generation implant-free ab interno canaloplasty system for adult patients with primary open-angle glaucoma Omni Ultra enables single-pass ...
VEO Ophthalmics will serve as the exclusive commercialization partner for VitaPixel SVS, while VitaPixel focuses on manufacturing and future R&D VitaPixel SVS adds stereoscopic 3D digital ...
In the phase 1/2 LUCE-1 study, no serious adverse events or dose-limiting toxicities had been reported among 15 participants treated with AAVB-081, while preliminary visual function improvements were ...
Eyestem reported interim phase 2 findings for Eyecyte-RPE, an investigational RPE cell therapy for GA secondary to dry AMD, with 24 participants enrolled in the randomized controlled study Early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results